#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Dementia Alzheimer's type Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Inclusion body myositis Hypergammaglobulinaemia benign monoclonal Congenital generalised lipodystrophy Neonatal alloimmune thrombocytopenia Inflammatory myofibroblastic tumour Gastrointestinal disorder Waldenstrom's macroglobulinaemia Peritoneal neoplasm Diffuse large B-cell lymphoma recurrent Salivary gland cancer Mantle cell lymphoma Carcinoid syndrome Polycystic liver disease Hydrocephalus Non-small cell lung cancer More trials…

    Learn about Rare Diseases

    Hereditary optic atrophy – Life with Disease Gaucher’s disease type III – Treatment Hyperoxaluria – Life with Disease Antisynthetase syndrome – Diagnostics Mantle cell lymphoma stage IV – Treatment Nephrotic syndrome – Basic Information Hairy cell leukaemia – Life with Disease Pleural mesothelioma malignant – Treatment Haemophilia A with anti factor VIII – Diagnostics Methylmalonic acidaemia – Treatment More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    GRISNILIMAB SETARITOX GOCATAMIG Maraviroc Triheptanoin Nacystelyn Carboplatin A/(H3N2)-LIKE VIRUS ANTIGEN VG801-1 Metoprolol Tartrate Olopatadine Ladarixin Sitagliptin TAZAROTENE Incb099280 Xtmab-16 Valiltramiprosate Dosulepin Hydrochloride Pd01B Infigratinib Tapentadol Hydrochloride More therapies…

    Learn about Your Condition

    H1N1 influenza Cervix carcinoma Bartonellosis Macular telangiectasia Influenza Phenylketonuria Gestational diabetes Endometrial cancer stage III Hypertriglyceridaemia Chondrocalcinosis Hypoparathyroidism Albuminuria Testicular leiomyosarcoma Pancreaticoduodenectomy Factor VIII deficiency More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Uncategorized

  • Study on the Effects of Rivaroxaban in Patients with Short Bowel Syndrome on Long-Term Parenteral Nutrition

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Short-bowel syndrome
    Investigated Drugs:
    • Rivaroxaban
    The Netherlands

  • Study on the Physical Impact of Multiple Sclerosis and Continued Access to Ocrelizumab for Patients Previously in a Related Study

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Ocrelizumab
    Bulgaria France Germany

  • Study on PET Imaging with Fianlimab and Cemiplimab for Patients with Advanced Solid Tumors, with or without Platinum-Based Chemotherapy

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Malignant melanoma
    • Microsatellite instability cancer
    • Cervix carcinoma
    Investigated Drugs:
    • Fianlimab
    • Cemiplimab
    The Netherlands

  • Study on the Effect of Lutropin Alfa to Improve Ovarian Reserve in Patients Undergoing IVF/ICSI Due to Tubal, Male Factor, or Unexplained Infertility

    Recruiting

    2 1 1 1
    Investigated Drugs:
    • Lutropin Alfa
    Italy

  • Study on Cemiplimab for Patients with High-Risk Stage III/IV Cutaneous Squamous Cell Carcinoma

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Squamous cell carcinoma of skin
    Investigated Drugs:
    • Cemiplimab
    Italy

  • Study on the Safety of Faster Infusions for Cancer Patients Using Trastuzumab, Bevacizumab, and Atezolizumab

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Inflammatory bowel disease
    • Rheumatic disorder
    Investigated Drugs:
    • Vedolizumab
    • Ipilimumab
    • Atezolizumab
    The Netherlands
Previous Page
1 … 309 310 311 312 313 … 1,649
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!